MRNA · Moderna, Inc.
$198.85
-0.62% last session
End-of-day data · close of 2026-10-26
Market cap
$79B
Enterprise value
$76B
Trailing P/E
—
Forward P/E
-43.5
Dividend yield
0.0%
Beta
1.10
Avg volume
21M
Employees
5K
Daily Change %
-0.62%
5 Days Change
-1.87%
10 Days Change
-8.79%
30 Days Change
-0.02%
60 Days Change
44.10%
Month to Day Change
5.25%
Year to Day Change
574.30%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MRNA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-26
Latest call per bank · past 12 months
Goldman Sachs
Neutral$137
-31.1% vs priceMorgan Stanley
Equal-Weight$95.00
-52.2% vs priceCitigroup
Sell$80.00
-59.8% vs priceBarclays
Equal-Weight$125
-37.1% vs priceJP Morgan
Underweight$77.00
-61.3% vs priceUBS
Neutral$150
-24.6% vs priceRBC Capital
Sector Perform$45.00
-77.4% vs priceBank of America
Underperform$38.00
-80.9% vs priceJefferies
Hold$30.00
-84.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-26 | Piper Sandler | Reiterates | Overweight | $167 → $230 |
| 2026-10-21 | TD Cowen | Maintains | Hold | $40.00 → $90.00 |
| 2026-10-15 | Goldman Sachs | Maintains | Neutral | $120 → $137 |
| 2026-10-07 | Morgan Stanley | Maintains | Equal-Weight | $89.00 → $95.00 |
| 2026-09-30 | Citigroup | Downgrade | Neutral → Sell | $60.00 → $80.00 |
| 2026-09-03 | Rothschild & Co | Downgrade | Neutral → Sell | $40.00 → $81.00 |
| 2026-08-28 | Argus Research | Upgrade | Hold → Buy | $0.00 → $180 |
| 2026-08-25 | Wolfe Research | Upgrade | Underperform → Peer Perform | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 14.4% above the 50-day MA ($173.86).
- bullish: Price vs 200-day MA: Trading 139.6% above the 200-day MA ($82.99).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-4.83) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($22.36) and high ($245.81).
MRNA Price Chart
Loading chart for MRNA…
Fundamentals
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
GMAB
Genmab A/S
$27B 45.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.